UY24498A1 - LACTAMA DERIVATIVES OF BENCIL AND BENCILIDENO AS AGONISTS AND SELTATIVE ANTAGONISTS OF 5-HT1A AND 5-HT1D RECEPTORS - Google Patents
LACTAMA DERIVATIVES OF BENCIL AND BENCILIDENO AS AGONISTS AND SELTATIVE ANTAGONISTS OF 5-HT1A AND 5-HT1D RECEPTORSInfo
- Publication number
- UY24498A1 UY24498A1 UY24498A UY24498A UY24498A1 UY 24498 A1 UY24498 A1 UY 24498A1 UY 24498 A UY24498 A UY 24498A UY 24498 A UY24498 A UY 24498A UY 24498 A1 UY24498 A1 UY 24498A1
- Authority
- UY
- Uruguay
- Prior art keywords
- disorders
- hydrogen
- antagonists
- agonists
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a derivados de lactama, a procedimientos y a intermedios para su preparación, a composiciones farmacéuticas que los contienen y a su uso en medicina. Los compuestos de la presente invención incluyen agonistas y antagonistas selectivos de receptores de serotonina 1 (5-HT1), específicamente, de uno o de los dos receptores 5-HT1A y 5-HT1D. Son útiles en el tratamiento o prevención de la migrana, depresión y otros trastornos para los que están indicados los agonistas o antagonistas de 5-HT1. Un compuesto de la fórmula (I) o una sal farmacéuticamente aceptable del mismo, en la que: R1 es un grupo de la fórmula G1, G2, G3, G4 ó G5, representados como figura 2, en las que E es oxígeno, azufre, SO o SO2; R2 es hidrógeno; R3 es (CH2)mB, donde m es 0, 1, 2 o 3 y B es hidrógeno, fenilo, naftilo, furilo, tienilo, piridilo, pirimidilo, tiazolilo, pirazolilo, isotiazolilo, oxazolilo, isoxazolilo, pirrolilo, triazolilo, tetrazolilo, imidazolilo, y donde cada uno de los grupos arilo y heteroarilo anteriores pueden estar opcionalmente sustituidos; Z es CR4R5, donde R4 y R5 se seleccionan independientemente entre hidrógeno, alquilo y trifluorometilo; ó Z puede ser furilo, tienilo, piridilo, pirimidilo, tiazolilo, pirazolilo, isotiazolilo, oxazolilo, isoxazolilo, pirrolilo, triazolilo, tetrazolilo, imidazolilo y donde dos miembros adyacentes en el anillo de Z también son miembros del anillo A; X es hidrógeno, cloro, fluoro, bromo, yodo, ciano, alquilo, hidroxi, trifluorometilo, alcoxi, Sog-alquilo donde g es 0, 1 o 2, CO2R10 ó CONR11R12; n es 1, 2, 3 o 4; y la línea discontinua indica un doble enlace opcional; con la condición de que n tiene qe ser 1 cuando Z es un grupo heteroarilo. Por ejemplo: 3-(2-(4-metilpiperazin-1-il)-bencilideno)-1,3-dihidro-indol-2-ona. Estos compuestos son útiles en un mamífero como agentes psicoterapéuticos, como ser en depresión, trastornos de ansiedad generalizada, fobias, pánico, Alzheimer, Parkinson, entre otros; para hipertensión disfunción sexual, trastornos de alimentación, obesidad, cefaleas, migranas, trastornos endocrinos, trastornos del tracto gastrointestinal, entre otras.The present invention relates to lactam derivatives, to processes and to intermediates for their preparation, to pharmaceutical compositions containing them and to their use in medicine. The compounds of the present invention include selective serotonin 1 (5-HT1) receptor agonists and antagonists, specifically, one or both of the 5-HT1A and 5-HT1D receptors. They are useful in the treatment or prevention of migraine, depression and other disorders for which 5-HT1 agonists or antagonists are indicated. A compound of the formula (I) or a pharmaceutically acceptable salt thereof, in which: R1 is a group of the formula G1, G2, G3, G4 or G5, represented as figure 2, in which E is oxygen, sulfur , SO or SO2; R2 is hydrogen; R3 is (CH2) mB, where m is 0, 1, 2 or 3 and B is hydrogen, phenyl, naphthyl, furyl, thienyl, pyridyl, pyrimidyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, and where each of the above aryl and heteroaryl groups may be optionally substituted; Z is CR4R5, where R4 and R5 are independently selected from hydrogen, alkyl, and trifluoromethyl; or Z may be furyl, thienyl, pyridyl, pyrimidyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl and where two adjacent members in the ring of Z are also members of ring A; X is hydrogen, chlorine, fluoro, bromine, iodine, cyano, alkyl, hydroxy, trifluoromethyl, alkoxy, Sog-alkyl where g is 0, 1 or 2, CO2R10 or CONR11R12; n is 1, 2, 3 or 4; and the dashed line indicates an optional double bond; with the proviso that n has qe to be 1 when Z is a heteroaryl group. For example: 3- (2- (4-methylpiperazin-1-yl) -benzylidene) -1,3-dihydro-indole-2-one. These compounds are useful in a mammal as psychotherapeutic agents, such as in depression, generalized anxiety disorders, phobias, panic, Alzheimer's, Parkinson's, among others; for hypertension, sexual dysfunction, eating disorders, obesity, headaches, migraines, endocrine disorders, disorders of the gastrointestinal tract, among others.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1513496P | 1996-03-29 | 1996-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY24498A1 true UY24498A1 (en) | 2000-09-29 |
Family
ID=21769713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY24498A UY24498A1 (en) | 1996-03-29 | 1997-03-21 | LACTAMA DERIVATIVES OF BENCIL AND BENCILIDENO AS AGONISTS AND SELTATIVE ANTAGONISTS OF 5-HT1A AND 5-HT1D RECEPTORS |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US6462048B2 (en) |
| EP (1) | EP0894085B1 (en) |
| JP (1) | JP3118467B2 (en) |
| KR (1) | KR100305071B1 (en) |
| CN (1) | CN1128788C (en) |
| AP (1) | AP824A (en) |
| AR (1) | AR006390A1 (en) |
| AT (1) | ATE302182T1 (en) |
| AU (1) | AU706839B2 (en) |
| BG (1) | BG64176B1 (en) |
| BR (1) | BR9708581A (en) |
| CA (1) | CA2249603A1 (en) |
| CO (1) | CO4650033A1 (en) |
| CZ (1) | CZ293628B6 (en) |
| DE (1) | DE69733996T2 (en) |
| DZ (1) | DZ2198A1 (en) |
| EA (1) | EA001485B1 (en) |
| ES (1) | ES2246058T3 (en) |
| HK (1) | HK1019446A1 (en) |
| HN (1) | HN1997000023A (en) |
| HR (1) | HRP970175A2 (en) |
| HU (1) | HUP9902160A3 (en) |
| ID (1) | ID17781A (en) |
| IL (1) | IL125377A (en) |
| IS (1) | IS4813A (en) |
| MA (1) | MA26425A1 (en) |
| MY (1) | MY118498A (en) |
| NO (1) | NO312957B1 (en) |
| NZ (1) | NZ325914A (en) |
| OA (1) | OA10879A (en) |
| PL (1) | PL329170A1 (en) |
| SK (1) | SK131498A3 (en) |
| TN (1) | TNSN97056A1 (en) |
| TR (1) | TR199801929T2 (en) |
| TW (1) | TW413679B (en) |
| UA (1) | UA70284C2 (en) |
| UY (1) | UY24498A1 (en) |
| WO (1) | WO1997036867A1 (en) |
| YU (1) | YU11997A (en) |
| ZA (1) | ZA972690B (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH041367U (en) * | 1990-04-13 | 1992-01-08 | ||
| US6906093B2 (en) | 1995-06-07 | 2005-06-14 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
| US6147106A (en) | 1997-08-20 | 2000-11-14 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US6696448B2 (en) * | 1996-06-05 | 2004-02-24 | Sugen, Inc. | 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors |
| US6423708B1 (en) * | 1996-09-30 | 2002-07-23 | Pfizer Inc | Aralkyl and aralkylidene heterocyclic lactams and imides |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6531502B1 (en) | 1998-01-21 | 2003-03-11 | Sugen, Inc. | 3-Methylidenyl-2-indolinone modulators of protein kinase |
| DE19830201A1 (en) * | 1998-07-07 | 2000-01-13 | Boehringer Ingelheim Pharma | Antidepressant |
| CA2301899C (en) * | 1998-07-27 | 2008-11-18 | Boehringer Ingelheim Pharma Kg | Agent with an antidepressant activity |
| US6624171B1 (en) | 1999-03-04 | 2003-09-23 | Smithkline Beecham Corporation | Substituted aza-oxindole derivatives |
| GB9904933D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
| US6492398B1 (en) | 1999-03-04 | 2002-12-10 | Smithkline Beechman Corporation | Thiazoloindolinone compounds |
| EP1113015B1 (en) * | 1999-12-29 | 2004-09-15 | Pfizer Products Inc. | Optically active 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists |
| US6620818B1 (en) | 2000-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Method for reducing the severity of side effects of chemotherapy and/or radiation therapy |
| MXPA04003385A (en) | 2001-10-10 | 2005-04-11 | Sugen Inc | 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors. |
| AU2003214800A1 (en) | 2002-01-02 | 2003-07-24 | Ardent Pharmaceuticals, Inc. | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds |
| TWI263497B (en) * | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
| DK1689721T3 (en) * | 2003-11-26 | 2010-09-20 | Pfizer Prod Inc | Aminopyrazole derivatives as GSK-3 inhibitors |
| JP2007537151A (en) * | 2004-01-29 | 2007-12-20 | ファイザー・プロダクツ・インク | Combination of γ-aminobutyric acid modulator and 5-HT1B receptor antagonist |
| AU2005223481A1 (en) | 2004-03-17 | 2005-09-29 | Pfizer Products Inc. | Novel benzyl(idene)-lactam derivatives |
| CA2565996A1 (en) * | 2004-05-11 | 2005-11-17 | Pfizer Products Inc. | Combination of atypical antipsychotics and 5-ht1b receptor antagonists |
| MXPA06012347A (en) * | 2004-05-21 | 2007-01-17 | Pfizer Prod Inc | Pyrazinylmethyl lactam derivatives. |
| JP2008503559A (en) * | 2004-06-25 | 2008-02-07 | ファイザー・プロダクツ・インク | Pyridylpiperazine for treating CNS disorders |
| ES2371927T3 (en) | 2005-01-13 | 2012-01-11 | Ge Healthcare Limited | BENCIL-LACTAMA COMPOUNDS MARKED WITH 11C AND ITS USE AS IMAGE OBTAINING AGENTS. |
| WO2006106416A1 (en) * | 2005-04-08 | 2006-10-12 | Pfizer Products Inc. | PYRIDIL-LACTAMS AND THEIR USE 5 -HTl RECEPTORS LIGAN |
| EP1891041A1 (en) * | 2005-06-17 | 2008-02-27 | Pfizer Products Incorporated | METABOLITES OF 1- [-6- (1-ETHYL-l-HYDROXY-PROPYL) -PYRIDIN-3-YL]-3- [2- (4-METHYL-PIPERAZIN-I-YL) -BENZYL]-PYRR0LIDIN-2-0NE AS SERATONIN RECEPTOR ANTAGONISTS |
| WO2007012964A1 (en) * | 2005-07-25 | 2007-02-01 | Pfizer Products Inc. | Preparation of alkylpiperazinylphenyl compounds by classical resolution |
| WO2007026224A2 (en) * | 2005-08-31 | 2007-03-08 | Pfizer Products Inc. | 5-ht1b antagonist composition for depression, anxiety and cognition |
| WO2007026219A2 (en) * | 2005-08-31 | 2007-03-08 | Pfizer Products Inc. | Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions |
| US20070096411A1 (en) * | 2005-11-02 | 2007-05-03 | Rempe Gary L Ii | Device for retaining a kneeling rider on a gliding board |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| SI3344248T1 (en) | 2015-09-02 | 2022-07-29 | Trevena, Inc. | 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
| BR112019016775A2 (en) | 2017-02-17 | 2020-03-31 | Trevena, Inc. | DELTA-OPIOIDE MODULATING RECEIVER COMPOUNDS CONTAINING 7-MEMBER AZA-HETEROCYCLIC, METHODS OF USE AND PRODUCTION OF THE SAME |
| CN110520129A (en) | 2017-02-17 | 2019-11-29 | 特维娜有限公司 | Delta opiate receptor modulating compound and its use and preparation method containing 5 yuan of aza heterocycles |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4078062A (en) * | 1976-10-28 | 1978-03-07 | E. R. Squibb & Sons, Inc. | Substituted 2H-1,4-benzothiazin-3(4H)-ones |
| JPS62116557A (en) * | 1985-11-15 | 1987-05-28 | Takeda Chem Ind Ltd | Substituted benzyl lactam |
| US5189179A (en) | 1990-08-29 | 1993-02-23 | Merrell Dow Pharmaceuticals Inc. | Serotonin 5ht1a agonists |
| ES2162792T3 (en) | 1991-09-18 | 2002-01-16 | Glaxo Group Ltd | BENZANILIDE DERIVATIVES AS 5-HT1D ANTAGONISTS. |
| AU2871592A (en) * | 1991-10-11 | 1993-05-03 | Du Pont Merck Pharmaceutical Company, The | Cyclic ureas and analogues useful as retroviral protease inhibitiors |
| US5436246A (en) | 1992-09-17 | 1995-07-25 | Merrell Dow Pharmaceuticals Inc. | Serotonin receptor agents |
| GB9410512D0 (en) * | 1994-05-25 | 1994-07-13 | Smithkline Beecham Plc | Novel treatment |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US6467084B1 (en) * | 1999-12-16 | 2002-10-15 | Emware, Inc. | Systems and methods for reprogramming an embedded device with program code using relocatable program code |
-
1997
- 1997-02-03 US US09/155,215 patent/US6462048B2/en not_active Expired - Fee Related
- 1997-02-03 CN CN97193251A patent/CN1128788C/en not_active Expired - Fee Related
- 1997-02-03 PL PL97329170A patent/PL329170A1/en unknown
- 1997-02-03 CZ CZ19983052A patent/CZ293628B6/en not_active IP Right Cessation
- 1997-02-03 NZ NZ325914A patent/NZ325914A/en unknown
- 1997-02-03 EA EA199800771A patent/EA001485B1/en not_active IP Right Cessation
- 1997-02-03 EP EP97900717A patent/EP0894085B1/en not_active Expired - Lifetime
- 1997-02-03 IL IL12537797A patent/IL125377A/en not_active IP Right Cessation
- 1997-02-03 HU HU9902160A patent/HUP9902160A3/en unknown
- 1997-02-03 KR KR1019980707713A patent/KR100305071B1/en not_active IP Right Cessation
- 1997-02-03 AU AU13170/97A patent/AU706839B2/en not_active Ceased
- 1997-02-03 CA CA002249603A patent/CA2249603A1/en not_active Abandoned
- 1997-02-03 BR BR9708581A patent/BR9708581A/en not_active Application Discontinuation
- 1997-02-03 WO PCT/IB1997/000076 patent/WO1997036867A1/en active IP Right Grant
- 1997-02-03 TR TR1998/01929T patent/TR199801929T2/en unknown
- 1997-02-03 SK SK1314-98A patent/SK131498A3/en unknown
- 1997-02-03 JP JP09535074A patent/JP3118467B2/en not_active Expired - Fee Related
- 1997-02-03 ES ES97900717T patent/ES2246058T3/en not_active Expired - Lifetime
- 1997-02-03 AT AT97900717T patent/ATE302182T1/en not_active IP Right Cessation
- 1997-02-03 DE DE69733996T patent/DE69733996T2/en not_active Expired - Fee Related
- 1997-02-04 TW TW086101295A patent/TW413679B/en active
- 1997-02-06 HN HN1997000023A patent/HN1997000023A/en unknown
- 1997-03-02 UA UA98095077A patent/UA70284C2/en unknown
- 1997-03-13 CO CO97013714A patent/CO4650033A1/en unknown
- 1997-03-21 UY UY24498A patent/UY24498A1/en not_active IP Right Cessation
- 1997-03-25 AR ARP970101200A patent/AR006390A1/en not_active Application Discontinuation
- 1997-03-26 DZ DZ970045A patent/DZ2198A1/en active
- 1997-03-26 TN TNTNSN97056A patent/TNSN97056A1/en unknown
- 1997-03-26 MA MA24535A patent/MA26425A1/en unknown
- 1997-03-26 HR HR60/015,134A patent/HRP970175A2/en not_active Application Discontinuation
- 1997-03-27 AP APAP/P/1997/000955A patent/AP824A/en active
- 1997-03-27 YU YU11997A patent/YU11997A/en unknown
- 1997-03-27 ZA ZA972690A patent/ZA972690B/en unknown
- 1997-03-27 ID IDP971025A patent/ID17781A/en unknown
- 1997-03-28 MY MYPI97001340A patent/MY118498A/en unknown
-
1998
- 1998-07-29 IS IS4813A patent/IS4813A/en unknown
- 1998-09-16 OA OA9800170A patent/OA10879A/en unknown
- 1998-09-24 BG BG102791A patent/BG64176B1/en unknown
- 1998-09-28 NO NO19984513A patent/NO312957B1/en unknown
-
1999
- 1999-10-13 HK HK99104493A patent/HK1019446A1/en not_active IP Right Cessation
-
2002
- 2002-08-15 US US10/219,692 patent/US6924289B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY24498A1 (en) | LACTAMA DERIVATIVES OF BENCIL AND BENCILIDENO AS AGONISTS AND SELTATIVE ANTAGONISTS OF 5-HT1A AND 5-HT1D RECEPTORS | |
| NO20052728L (en) | Substituted tricyclic gamma-carbolines such as serotonin receptor agonists and antagonists | |
| BR112016022785B1 (en) | TRYPTOPHANE-2,3-DIOXYGENASE INHIBITOR COMPOUND (TDO) AND / OR INDOLEAMINE-2,3-DIOXYGENASE (IDO), PHARMACEUTICAL COMPOSITION, AND USE OF TRYPTOPHANE-2,3-DIOXYGENASE (TDO) INHIBITOR AND / OR INDOLEAMINE-2,3DIOXYGENASE (IDO) OR PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME FOR MANUFACTURE OF A MEDICINAL PRODUCT | |
| CZ297183B6 (en) | Use of substituted pyrazolyl benzenesulfonamides in veterinary therapy | |
| ES2260958T3 (en) | RECEIVER SELECTIVE LINKS 5 - HT 6. | |
| ES2279125T3 (en) | DERIVATIVES OF 1- (AMINOALQUIL) -3-SULFONYLINDOL E-INDAZOL AS 5-HYDROXYTHYRIPTAMINE-6 LIGANDS. | |
| CO5031253A1 (en) | RECEIVING ANTAGONISTS Y5 OF NEUROPEPTIDES PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| ES2277330T3 (en) | 5-HT4 RECEIVER ANTAGONISTS. | |
| KR20080089416A (en) | Compositions and methods for modulating gated ion channels | |
| NO20032798L (en) | Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists | |
| HUT74090A (en) | Indole derivatives, process for producing them and pharmaceutical compositions containing them | |
| JP2009516712A (en) | Compositions and methods for modulating gated ion channels | |
| RU2007107494A (en) | Tricyclic derivatives of indenopyrrole as modulators of serotinin receptors, a pharmaceutical composition based on them, and a method for treating diseases, and / or non-trivial necrosis. | |
| ATE493404T1 (en) | AZABICYCLO-(3,1,0)-HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | |
| ES2303960T3 (en) | DERIVATIVES OF 2- (1H-INDOLILSULFANIL) -BENCILAMINE AS SSRI. | |
| PE20060457A1 (en) | DIPHENYL ETHER DERIVATIVES AS ANTAGONISTS OF 5HT2 RECEPTORS | |
| CA2120028C (en) | Indol derivatives for the treatment of migrane | |
| EA200300519A1 (en) | CONNECTIONS OF DERIVATIVES OF BENZOTHIOPHENE, THE METHOD OF THEIR RECEPTION AND APPLICATION | |
| AR015446A1 (en) | ANTIGONISTS OF VITRONECTINE RECEPTORS, PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR PREPARATION, ITS USE FOR THE PREPARATION OF A MEDICINE AND INTERMEDIATE COMPOUNDS | |
| RU2005122615A (en) | COMPOUNDS N- (INDOLETHYL) CYCLOAMINE | |
| JP2008525398A5 (en) | ||
| ES2234683T3 (en) | ISOQUINOLINE AND QUINAZOLINE DERIVATIVES WITH COMBINED ACTIVITY ON THE 5HT1A, 5HT1B AND 5HT1D RECEPTORS. | |
| JP3883567B2 (en) | N-substituted azabicycloheptane derivatives, such as neuroleptic agents | |
| JP2006503857A5 (en) | ||
| AR052332A1 (en) | DERIVATIVES OF BENZDIOXANPIPERAZINE WITH A COMBINED AFFINITY FOR DOPAMINE-D2 RECEPTORS AND SEROTONINE REABSORTION SITES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS MEDICINES FOR THE TREATMENT OF CNS DISEASES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| VENC | Patent expired |
Effective date: 20170321 |